Hidradenitis suppurativa, intestinal microbiome and SIBO – a comprehensive overview of the issue

Česká verze

Authors: B. Ivanková ¹ ; J. Baloghová ^1,2
Authors place of work: Klinika dermatovenerológie UN L. Pasteura, Košice ¹; LF UPJŠ Košice ²
Published in the journal: Gastroent Hepatol 2024; 78(1): 41-46
Category: Klinická a experimentální gastroenterologie: přehledová práce
doi: https://doi.org/10.48096/ccgh202441

Summary

Hidradenitis suppurativa (HS) is a chronic immune-mediated inflammatory skin disease. It is characterized by an inflammation that affects apocrine gland bearing skin in axillae, groin and under the breasts with the formation of painful nodules, abscesses and purulent discharge, sinuses and scaring. Patients with HS have an increased incidence of inflammatory bowel disease (IBD), which also indicates their cross-sections in the pathogenesis of dysregulation congenital and adaptive immunity. Recently, there has been a significant increase of interest in the intestinal microbiome and skin disease, as much as its role in the pathogenesis of HS. According to literature, intestinal dysbiosis promotes the production of proinflammatory cytokines and consequently the formation of HS lesions. Overgrowth of bacteria in the small intestine (SIBO) is a condition characterized by an increased concentration of bacteria in the large intestine. Eradication of SIBO was able to improve psoriasis measured by the psoriasis severity index. In this context, it is hypothesized that eredication of SIBO may have a beneficial effect on the severity of manifestations in inflammatory immune-mediated skin diseases, including HS.

Keywords:

hidradenitis suppurativa – immune-mediated infl ammation – gut microbio me – small intestinal bacterial overgrowth – SIBO – interprofessional cooperation

Zdroje

1. Sabat R, Jemec GBE, Matusiak Ł et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6(1): 18. doi: 10.1038/ s41572-020-0149-1.

2. Van der Zee HH, Riuter L, Broecke DG et al. Elevated levels of tumor necrosis factor alfa, interleukin 1 beta in hidradenitis suppurativa skin: a rationale for targeting TNF alfa and Il beta. Br J Dermatol 2011; 164(6): 1292–1298. doi: 10.1111/ j.1365-2133.2011.10254.x.

3. Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa. J Am Acad Dermatol 2015; 73(5 suppl 1): S8–S11. doi: 10.1016/ j.jaad.2015.07.045.

4. Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J Am Acad Dermatol 2008; 59(4): 596–601. doi: 10.1016/ j.jaad.2008.06.020.

5. Kimball AB, Jemec GB, Yang M et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatement. Br J Dermatol 2014; 171(6): 1434–1442. doi: 10.1111/ bjd.13270.

6. Kohorst J, Baum C, Otley C et al. Surgical management of Hidradenitis Suppurativa. Dermatol Surg 2016; 42(9): 1030–1040. doi: 10.1097/ DSS.0000000000000806.

7. Ursell LK, Metcalf JL, Partfrey lW et al. Defining the human microbiome. Nutr Rev 2012; 70(1): S38–S44. doi: 10.1111/ j.1753-4887.2012.00493.x.

8. Heintz-Buschart A, Wilmes P. Human Gut Microbiome: Function Matters. Trends Microbiol 2018; 26(7): 563–574. doi: 10.1016/ j.tim.2017.11.002.

9. Świerczewska Z, Lewandowski M, Surowiecka A et al. Microbiome in Hidradenitis Suppurativa – What We Know and Where We are Heading. Int J Mol Sci 2022; 23(19): 11280. doi: 10.3390/ ijms231911280.

10. Molnar J, Mallonee CJ, Stanisic D et al. Hidradenitis suppurativa and 1-CarbonMetabolism: Role of Gut Microbiome, matrix Metalloproteinases and Hyperhomocysteinemia. Front Immunol 2020; 11: 1730. doi: 10.3389/ fimmu.2020.01730.

11. McCarthy S, Barret M, Kirthi S et al. Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. J Invest Dermatol 2021; 142(2): 459–468. doi: 10.1016/ j.jid.2021.05.036.

12. Kam S, Collard M, Lam J et al. Gut Microbiome Pertubations in patients with Hidradenitis Suppurativa: A Case Series. J Invest Dermatol 2021; 141(1): 225–228. doi: 10.1016/ j.jid.2020.04.017.

13. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (NY) 2007; 3(2): 112–122.

14. Losurdo G, Salvatore D‘Abramo F, Indellicati G et al. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci 2020; 21(10): 3531. doi: 10.3390/ ijms21103531.

15. Shah A, Morrison M, Burger D et al. Systematic Review with metaanalysis: The prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther 2019; 49(6): 624–635. doi: 10.1111/ apt.15133.

16. Weinstock LB, Steinhoff M. Rosecea and small intestinal bacterial overgrowth: Prevalence and response to rifaximin. J Am Acad Dermatol 2013; 68(5): 875–876. doi: 10.1016/ j.jaad.2012.11.038.

17. Salem I, Ramser A, Isham N, Ghannoum MA. The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. Front Microbiol 2018; 9: 1459. doi: 10.3389/ fmicb.2018.01459.

18. Drago F, Ciccarese G, Indemini E et al. Psoriasis and small intestine bacterial overgrowth. Int J Dermatol 2018; 57(1): 112–113. doi: 10.1111/ ijd.13797.

19. Miller IM, Ellervik C, Vinding GR et al. Associoation of metabolic syndrome and hidradenitis suppurativa. AMA Dermatol 2014; 150(12): 1273–1280. doi: 10.1001/ jamadermatol.2014.1165.

20. Vorčáková K, Péčová K, Madleňák M et al. Hidradenitis suppurativa – terapeutická výzva pre dermatológa. Dermatol Prax 2021; 15(2): 62–67.

21. Zhang M, Chen QD, Xu HX et al. Association of hidradenitis suppurativa with Crohn’s disease. World J Clin Cases 2021; 9(15): 3506–3516. doi: 10.12998/ wjcc.v9.i15.3506.

22. Chen WT, Chi CC. Association of Hidradenitis suppurativa With Inflamatory Bowel Disease: A systemic Review and meta-analysis. JAMA Dermatol 2019; 155(9): 1022–1027. doi: 10.1001/ jamadermatol.2019.0891.

23. Monnier L, Dohan A, Amara N et al. Anoperineal disease in Hidradenitis suppurativa: MR imaging distinction from perianal Crohn’s disease. Eur Radiol. 2017; 27(10): 4100–4109. doi: 10.1007/ s00330-017-4776-1.

24. Kamal N, Cohen BL, Buche S et al. Features of Patients With Crohn’s Disease and Hidradenitis Suppurativa. Clin Gastroenterol Hepatol 2016; 14(1): 71–79. doi: 10.1016/ j.cgh.2015.04.180.

25. Manolitas T, Biankin S, Jaworski R et al. Vulval squamouscell carcinoma arising in chronic hidradenitis suppurativa a case report and rewiev of the literature. Int Wound J 2017; 14(2): 435–438. doi: 10.1111/ iwj.12671.

26. Tannebaum R, Strunk A, Garg A. Association between hidradenitis suppurativa and lymphoma. JAMA Dermatol 2019; 155(5): 624–625. doi: 10.1001/ jamadermatol.2018.5230.

27. Racanelli E, Jfri A, Gefri A et al. Cutaneous Squamous Cell Carcinoma in Patients with Hidradenitis Suppurativa. Cancers (Basel) 2021; 13(5): 1153. doi: 10.3390/ cancers13051153.

28. Gierek M, Niemiec P, Szyluk K et al. Hidradenitis supurrativa and squamous cell carcinoma: a systemic review of the literature. Postepy Dermatol Alegol 2023; 40(3): 350–354. doi: 10.5114/ ada.2023.126563.

29. Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/ acne inversa. J Eur Acad Dermatol Venereol 2015; 29(4): 619–644. doi: 10.1111/ jdv.12966.

30. Urbanček S, Vorčáková K. Aktuálna farmakoterapia Hidradenitis suppurativa. Dermatol Prax 2022; 16(1): 14–16.

ORCID autorov

B. Ivanková 0009-0005-6036-9357,

J. Baloghová 0000-0003-4470-5777.

Doručené/ Submitted: 8. 11. 2023
Prijaté/ Accepted: 6. 1. 2024

MU Dr. Barbara Ivanková, MBA
Klinika dermatovenerológie
UPJŠ LF a UN LP Košice
Trieda SNP 1
040 01 Košice
barbara.ivankova@unlp.sk